Nilotinib Stada (Nilotinib)

Nilotinib is a targeted therapy used in the management of chronic myeloid leukemia (CML), a disease driven by BCR‑ABL tyrosine‑kinase activity.

• Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and improves survival.
• Chronic myeloid leukemia (accelerated phase): helps achieve hematologic and cytogenetic responses.
• Chronic myeloid leukemia (blast phase): provides disease control when combined with other agents.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase, a constitutively active enzyme produced by the Philadelphia chromosome translocation. By blocking ATP binding to the kinase domain, it prevents downstream signaling that drives uncontrolled proliferation and survival of leukemic cells, leading to apoptosis and disease control.

Nilotinib may cause a range of adverse reactions, from mild to severe. Patients should be monitored regularly for any new or worsening symptoms.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: watery stools, often self‑limiting.
• Rash: skin erythema or pruritus.
• Headache: transient, usually low‑grade.
• Fatigue: generalized tiredness.
• Myalgia: muscle aches.

Serious or Rare Side Effects

• QT interval prolongation: risk of cardiac arrhythmia.
• Pancreatitis: abdominal pain with elevated enzymes.
• Severe liver injury: jaundice, elevated transaminases.
• Neutropenia: low white‑blood‑cell count increasing infection risk.
• Thrombocytopenia: reduced platelets leading to bleeding.
• Stevens‑Johnson syndrome: severe skin reaction requiring immediate care.

Nilotinib requires careful monitoring and patient education to minimize risks.

• Cardiac monitoring: obtain baseline ECG and repeat periodically to detect QT prolongation.
• Liver function: check ALT, AST, and bilirubin before starting and during therapy.
• Hematology: perform complete blood counts regularly to identify neutropenia or thrombocytopenia.
• Drug interactions: avoid strong CYP3A4 inhibitors that can increase nilotinib exposure.
• Hepatic impairment: dose adjustment may be needed in patients with moderate liver dysfunction.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nilotinib can interact with several drug classes, altering its plasma concentration or increasing toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib levels and heighten cardiac risk.
• Proton‑pump inhibitors (e.g., omeprazole) taken with nilotinib: can reduce absorption and efficacy.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug exposure.
• Antacids containing aluminum or magnesium: can affect nilotinib bioavailability if taken simultaneously.
• Anticoagulants (e.g., warfarin): monitor INR as nilotinib may affect metabolism.
• Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for muscle toxicity.